MOMS Act

The MOMS Act, S. 1630, was introduced in the Senate on May 6, 2025, and subsequently referred to the Committee on Health, Education, Labor, and Pensions. This bill is in the early stages of the legislative process. Its primary objective, as outlined in the bill text, is to amend the Public Health Service Act to establish a public website named 'pregnancy.gov' within one year of enactment, which would serve as a clearinghouse for resources for pregnant and postpartum women. The bill itself does not authorize specific funding amounts; rather, it directs the Secretary to establish the website. Therefore, while it creates a mandate for a new federal digital platform, the actual appropriation of funds for its development, maintenance, and associated services would require subsequent legislative action. The mechanism for funding would likely be through federal contracts awarded for web development, IT services, and potentially data management. Structural winners, should this bill advance and receive appropriations, would primarily be federal IT contractors and web development firms. Companies like Accenture ($ACN) and IBM ($IBM), which have significant federal contracting divisions and expertise in large-scale government IT projects, are well-positioned to bid on such opportunities. Accenture's current price is $198.95, with a 7-day change of +0.71% and a 30-day change of -7.03%. IBM's current price is $246.74, showing a 7-day change of +4% and a 30-day change of -3.82%. The bill's early stage means any market impact on these companies is speculative and not yet reflected in current price movements. Healthcare providers and organizations that could be listed on the website may also see increased visibility, but this is an indirect benefit. Given its early stage, the bill faces a lengthy legislative path, including committee review, potential amendments, and votes in both the Senate and House, followed by presidential assent. The presence of 23 cosponsors, including the lead sponsor Sen. Britt (R-AL), indicates some bipartisan support, but its referral to committee signifies that detailed consideration is just beginning.